IE 11 is not supported. For an optimal experience visit our site on another browser.

Apricus Biosciences Produces Videos Describing the Mechanism by Which Its NexACT(R) Technology Successfully Delivers Drugs Through the Skin

/ Source: GlobeNewswire

SAN DIEGO, June 1, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI), today announced that it has produced a series of online videos on the Company's NexACT® drug delivery technology, which enables the rapid absorption of various active pharmaceutical ingredients through the skin, with the goal of improving patient outcomes and reducing side effects. The videos are available at .

"This educational video series provides clear, concise answers to the general public about Apricus Bio's proprietary NexACT® technology, including a description of its science, chemical composition and biological interactions," stated Chairman, President and Chief Executive Officer, Dr. Bassam Damaj. "We believe that it is important for the public to understand this important drug delivery technology and its potential and to visually see how this technology successfully delivers drugs to the human body. The videos also serve to educate our industry colleagues on how NexACT® may improve the efficacy of their drugs and drug candidates."

Joining Edward Cox, Vice President of Corporate Development and Investor Relations at Apricus Bio on the NexACT® videos, are two experts from Apricus Bio's wholly-owned subsidiary, NexMed USA: Richard Martin, Vice President of Chemistry, and Dr. Mohamed Hachicha, Vice President-Research and Development. 

The videos are the second installment in Apricus Bio's educational series that began with a video series describing its first approved drug, Vitaros®, for erectile dysfunction. Apricus Bio has received approval to market Vitaros® in Canada and is proceeding with manufacturing of the drug. The Company currently anticipates that Vitaros® will be available to patients in Canada in the second half of 2011.

Other drugs in Apricus Bio's pipeline include: Femprox®, a treatment for female sexual arousal disorder; MycoVa®, for onychomycosis (nail fungus); PrevOnco™, a treatment for hepatocellular liver carcinoma; and RayVa™, for Raynaud's Syndrome.

About Apricus Biosciences, Inc.

Apricus Bio, a San Diego based revenue-generating pharmaceutical company, has leveraged the flexibility of its clinically-validated NexACT® drug delivery technology to enable multi-route administration of new and improved compounds across numerous therapeutic classes.

Revenues and growth are driven from out-licensing of this technology for the development and commercialization of such compounds to pharmaceutical and biotechnology companies worldwide. In addition, the Company is seeking to monetize its existing product pipeline, including its first product, Vitaros®, approved in Canada for the treatment of erectile dysfunction, which is currently expected to be available on the Canadian market in 2011, as well as compounds in development from pre-clinical through Phase III, currently focused on Sexual Dysfunction, Oncology, Dermatology, Autoimmune, Pain, Anti-Infectives, Diabetes and Cosmeceuticals among others.

For further information on Apricus Bio, visit and for information on its subsidiaries please visit or . You can also receive information at and .

Apricus Bio's Forward-Looking Statement Safe Harbor

Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, its ability to further development products and product candidates and the Company's NexACT® technology, to successfully commercialize such products and product candidates and to achieve its other development, commercialization and financial goals. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.

CONTACT: Apricus Biosciences, Inc. Edward Cox, V.P. Investor Relations & Corporate Development, Apricus Bio, Inc. (858) 848-4249 ecox@apricusbio.com Apricus Bio Investor Relations Paula Schwartz Rx Communications Group, LLC (917) 322-2216 pschwartz@rxir.com